ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...
Jan 12 (Reuters) - AbbVie said on Monday that it has struck a three-year deal with U.S. President Donald Trump's ...
Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback